MedTrace Logo

The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients

NCT05921058 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-06-27

No results posted yet for this study

Summary

This research is a clinical trial of administering mesenchymal stem cell secretome to lupus patients.

Conditions

  • Lupus Erythematosus

Interventions

DRUG

Secretome

Mesenchymal stem cell secretome obtained from Kalbe Pharma Company

DRUG

Placebo

NaCl 0,9% infusion

Sponsors & Collaborators

  • Universitas Sebelas Maret

    lead OTHER

Principal Investigators

  • Nurhasan Agung Prabowo, MD · Universitas Sebelas Maret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2022-12-30
Completion
2023-03-09

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05921058 on ClinicalTrials.gov